Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 23Prostatic Neoplasms 8Carcinoma, Intraductal, Noninfiltrating 3Thyroid Nodule 2Stomach Neoplasms 2Pleural Effusion, Malignant 2Mouth Neoplasms 2Fibrosis 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Uterine Hemorrhage 1Unspecified Adult Solid Tumor, Protocol Specific 1Thromboembolism 1Stomatitis 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma, Endometrial Stromal 1Risk Malignant Index 1Renal Insufficiency, Chronic 1Rectal Neoplasms 1Pheochromocytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neurofibrosarcoma 1Neurofibromatosis 1 1Neoplasms 1Melanoma 1Lymphedema 1

Interventions

selurampanel 1Postmortem Imaging 1Magnetic Resonance Spectroscopy 1High-Energy Shock Waves 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adrenocortical Adenoma × High-Energy Shock Waves × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡